Aliases & Classifications for Impetigo

MalaCards integrated aliases for Impetigo:

Name: Impetigo 12 75 43 44 15 63 17 72 33

Classifications:



External Ids:

Disease Ontology 12 DOID:8504
ICD9CM 35 684
MeSH 44 D007169
NCIt 50 C99088
SNOMED-CT 68 48277006
ICD10 33 L01 L01.0 L01.00
UMLS 72 C0021099

Summaries for Impetigo

MedlinePlus : 43 Impetigo is a skin infection caused by bacteria. It is usually caused by staphylococcal (staph) bacteria, but it can also be caused by streptococcal (strep) bacteria. It is most common in children between the ages of two and six. It usually starts when bacteria get into a break in the skin, such as a cut, scratch, or insect bite. Symptoms start with red or pimple-like sores surrounded by red skin. These sores can be anywhere, but usually they occur on your face, arms and legs. The sores fill with pus, then break open after a few days and form a thick crust. They are often itchy, but scratching them can spread the sores. Impetigo can spread by contact with sores or nasal discharge from an infected person. You can treat impetigo with antibiotics.

MalaCards based summary : Impetigo is related to impetigo herpetiformis and pustular psoriasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Impetigo is DSG1 (Desmoglein 1), and among its related pathways/superpathways are Lung fibrosis and Endothelins. The drugs Mupirocin and Retapamulin have been mentioned in the context of this disorder. Affiliated tissues include skin, colon and liver.

Disease Ontology : 12 A pyoderma consisting of three forms of skin lesions having either a thick, adherent, recurrent, dirty yellow crust with an erythematous margin (common or superficial impetigo) or lessions which are superficial, thin-walled, and bullous as found in bullous impetigo. The lesions in bullous (staphylococcal) impetigo, which are always caused by S aureus, are superficial, thin-walled, and bullous.

PubMed Health : 63 About impetigo: Impetigo is an itchy and sometimes painful infection of the outer layers of skin that is especially common in young children. It is caused by bacteria and is highly contagious. For that reason, children who have impetigo are not allowed to return to school or day care until they are no longer contagious – about 24 hours after the start of treatment with antibiotics. Without treatment, it can remain contagious for several weeks.

Wikipedia : 75 Impetigo is a bacterial infection that involves the superficial skin. The most common presentation is... more...

Related Diseases for Impetigo

Diseases related to Impetigo via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 impetigo herpetiformis 34.3 PI3 IL36RN ELANE
2 pustular psoriasis 32.6 PI3 IL36RN ELANE
3 bullous impetigo 32.5 IL6 EDNRB EDNRA DSG1 CALCA
4 ritter's disease 31.8 EDNRB EDNRA DSG1
5 pyoderma 31.0 IL36RN DSG1
6 skin disease 30.9 PI3 IL36RN DSG1
7 erysipelas 30.6 PI3 ELANE CALCA
8 streptococcal toxic-shock syndrome 30.2 MYOM2 IL6
9 rheumatic heart disease 30.1 MYOM2 IL6
10 rheumatic fever 29.8 MYOM2 IL6
11 scarlet fever 29.0 MYOM2 EDNRB EDNRA
12 connective tissue disease 29.0 IL6 EDNRB EDNRA
13 ecthyma 11.5
14 prolidase deficiency 11.2
15 acute proliferative glomerulonephritis 11.2
16 recessive dystrophic epidermolysis bullosa-generalized other 11.2
17 pustulosis of palm and sole 10.6
18 psoriasis 10.6
19 dermatitis 10.6
20 scabies 10.5
21 pemphigus 10.5
22 glomerulonephritis 10.5
23 engraftment syndrome 10.5 PI3 CALCA
24 dermatitis, atopic 10.4
25 farmer's lung 10.4 PI3 ELANE
26 pharyngitis 10.4
27 bronchopneumonia 10.4 PI3 ELANE
28 pustulosis palmaris et plantaris 10.4 IL36RN ELANE
29 dermatophytosis 10.4
30 psoriasis 14, pustular 10.4
31 hypoparathyroidism 10.4
32 acute cholangitis 10.3 IL6 CALCA
33 bacterial infectious disease 10.3
34 acrodermatitis 10.3
35 cellulitis 10.3
36 capillary leak syndrome 10.3 IL6 ELANE
37 bacterial sepsis 10.3 ELANE CALCA
38 exanthem 10.3
39 nodular goiter 10.3 IL6 CALCA
40 multiple endocrine neoplasia, type iib 10.2 EDNRB CALCA
41 complex regional pain syndrome 10.2 IL6 CALCA
42 gingival disease 10.2 IL6 ELANE
43 autonomic nervous system disease 10.2 EDNRB CALCA
44 placental insufficiency 10.2
45 pemphigus foliaceus 10.2
46 bone resorption disease 10.2 IL6 CALCA
47 miliaria rubra 10.2
48 miliaria 10.2
49 folliculitis 10.2
50 lupus erythematosus 10.2

Comorbidity relations with Impetigo via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Impetigo:



Diseases related to Impetigo

Symptoms & Phenotypes for Impetigo

UMLS symptoms related to Impetigo:


fever, pruritus, exanthema

Drugs & Therapeutics for Impetigo

PubMed Health treatment related to Impetigo: 63

As long as impetigo doesn't spread beyond a small patch of skin, disinfectant solutions or creams are often recommended. But it isn't clear whether they work. Antibiotic creams have proven effective. Antibiotics that are swallowed (oral antibiotics) are usually only prescribed if a child has impetigo on a large area of skin or if several parts of their body are affected. Antibiotic tablets are more likely to have side effects than antibiotic creams. For instance, they may cause gastrointestinal (stomach and bowel) problems. Good hygiene is the key to avoiding infection, especially washing hands frequently,not sharing towels, andwashing worn clothing at 60°C (140°F) or higher. It's a good idea to keep the child’s fingernails trimmed very short so they can't scratch themselves as much.

Drugs for Impetigo (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
2
Retapamulin Approved Phase 4 224452-66-8 6918462
3
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
4
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
5
Azithromycin Approved Phase 4 83905-01-5 447043 55185
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Petrolatum Approved, Investigational Phase 4 8009-03-8
8
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
9
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
10 Dermatologic Agents Phase 4
11 Antiparasitic Agents Phase 4
12 Immunosuppressive Agents Phase 4
13 Immunologic Factors Phase 4
14 Vasoconstrictor Agents Phase 4
15 Emollients Phase 4
16 Calcineurin Inhibitors Phase 4
17 Anti-Bacterial Agents Phase 4
18 Anti-Infective Agents Phase 4
19
Menthol Approved Phase 2, Phase 3 2216-51-5 16666
20
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
21
Zinc Approved, Investigational Phase 3 7440-66-6 32051
22
Malathion Approved, Investigational Phase 3 121-75-5 4004
23 Respiratory System Agents Phase 2, Phase 3
24 Expectorants Phase 2, Phase 3
25 Antipruritics Phase 2, Phase 3
26 Terpin Phase 2, Phase 3
27 Antibiotics, Antitubercular Phase 3
28 methicillin Phase 3
29 Neurotransmitter Agents Phase 3
30 Cholinesterase Inhibitors Phase 3
31 Cholinergic Agents Phase 3
32
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
33 Vaccines Phase 2
34 Antibodies Phase 2
35 Immunoglobulins Phase 2
36 Immunoglobulins, Intravenous Phase 2
37 gamma-Globulins Phase 2
38 Immunoglobulin G Phase 2
39 Rho(D) Immune Globulin Phase 2
40 Papaya Approved Phase 1
41
Diethylcarbamazine Approved, Investigational, Vet_approved 90-89-1 3052
42
Albendazole Approved, Vet_approved 54965-21-8 2082
43
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
44
Calcium Approved, Nutraceutical 7440-70-2 271
45
Vitamin D3 Approved, Nutraceutical 67-97-0 6221 5280795
46
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
47 Lipoxygenase Inhibitors
48 Tubulin Modulators
49 Liver Extracts
50 Anthelmintics

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
2 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Completed NCT01126268 Phase 4 Retapamulin (Altabax)
3 Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology Completed NCT02775617 Phase 4 Ivermectin;Azithromycin;Permethrin
4 A Double Blind Randomized Trial, Placebo-controled of 0.0003% Calcitriol Ointment Versus 0.1% Tacrolimus Ointment in the Treatment of Pityriasis Alba Completed NCT01388517 Phase 4 Tacrolimus;Calcitriol;Petrolatum
5 Retapamulin for Reducing MRSA Nasal Carriage Completed NCT01461668 Phase 4 Retapamulin;Placebo
6 A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients Terminated NCT00986856 Phase 4 Fucidin® cream
7 A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo. Unknown status NCT01611909 Phase 2, Phase 3 p-menthane-3,8-diol oil
8 A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo Completed NCT02090764 Phase 3 Ozenoxacin;Placebo
9 A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo. Completed NCT00133848 Phase 3 SB-275833 ointment, 1%
10 A Phase III 3 Arms, Multicenter, Randomised, Investigator-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo Completed NCT01397461 Phase 3 ozenoxacin placebo;retapamulin 1% ointment;ozenoxacin 1% cream
11 An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo Completed NCT00133874 Phase 3 SB-275833 ointment, 1%
12 A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo Completed NCT01670032 Phase 2, Phase 3 Experimental: CD07223 1.5 % Topical Gel BID;Experimental: CD07223 1.5% Topical Gel TID;Placebo Comparator: CD07223 vehicle gel BID;Placebo Comparator: CD07223 vehicle gel TID
13 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00852540 Phase 3 Retpamulin Ointment, 1%;Linezolid
14 Immunological and Clinical Responses to Zinc: A Randomized, Double-Blind Trial of Zinc Treatment vs. Zinc Treatment Plus Daily Supplementation for 3 Months Among Children Under 2 Years of Age With an Acute Diarrheal Illness. Completed NCT00408356 Phase 3 Zinc
15 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands Completed NCT03236168 Phase 3 Ivermectin;Permethrin 5%;Malathion Shampoo 0.5%
16 Randomized, Double-Blind, Vehicle Controlled, Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of Topical ATx201 GEL (2% and 4%) in Outpatients With Impetigo Completed NCT03429595 Phase 2 ATx201
17 The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo Completed NCT00758862 Phase 2 2% TD1414 Cream
18 A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo Completed NCT01171326 Phase 2 Topical Minocycline Foam FXFM244
19 Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) Completed NCT00626795 Phase 2 TD1414 2% cream;TD1414 2% cream;Bactroban® (mupirocin) 2% cream
20 A Phase II, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 (1 % and 2 %) Versus Placebo in Impetigo Completed NCT01803035 Phase 2 LTX-109 1 %;LTX-109 2 %;Placebo gel
21 A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo Completed NCT01367314 Phase 2 NVC-422
22 A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection Completed NCT01223222 Phase 2 LTX-109
23 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
24 The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT01943136 Phase 1 papaya 1% extract ointment;mupirocin 2% ointment
25 Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union Completed NCT01153828 Retapamulin;Co-prescription of retapamulin and topical mupirocin;Co-prescription of retapamulin and topical fusidic acid
26 Tele-dermatology of Skin Cancer: a Randomized Trial Comparing Remote Assessment With Conventional Visits in a Cohort of Local Health Authority Employees in the Province of Bergamo (the Shoot the Mole Study) Completed NCT02902822
27 An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information Completed NCT01445600 ALTARGO(retapamulin)
28 East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities Completed NCT00884728
29 Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections Completed NCT02010294
30 Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the United States Completed NCT01153880 Retapamulin;Co-prescription of retapamulin and topical mupirocin
31 Epidemiological Surveillance in India of Group A Streptococcal Infections Including Pharyngitis and Impetigo Supported by Indo-US Vaccine Action Program Completed NCT00342199
32 A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis Completed NCT01714245
33 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
34 Prospective Assessment of the Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH) Completed NCT00800449
35 Pilot Study To Determine The Underlying Mechanisms For Infection And Colonization By Staphylococcus Aureus Of The Skin Of Atopic Dermatitis Subjects With And Without A History Of Eczema Herpeticum (ADVN MRSA 10) Completed NCT00822276
36 Effectiveness of Vitamin D Supplementation to Reduce Injury and Illness in the UK Armed Forces With Specific Reference to Stress Fracture Risk Reduction Recruiting NCT03963128

Search NIH Clinical Center for Impetigo

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cefuroxime
Dicloxacillin
Gentamicin
Levofloxacin
Mupirocin
Ozenoxacin

Cochrane evidence based reviews: impetigo

Genetic Tests for Impetigo

Anatomical Context for Impetigo

MalaCards organs/tissues related to Impetigo:

41
Skin, Colon, Liver, Bone, Neutrophil, Testes, Breast

Publications for Impetigo

Articles related to Impetigo:

(show top 50) (show all 1459)
# Title Authors PMID Year
1
Ozenoxacin 1% cream (Xepi) for impetigo. 38 17
31169810 2019
2
Clonal change of methicillin-resistant Staphylococcus aureus isolated from patients with impetigo in Kagawa, Japan. 38 17
30803017 2019
3
Hydrochlorothizide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo. 38 17
30755424 2019
4
[Tinea barbae profunda due to Trichophyton mentagrophytes : Case report and review]. 38
31001659 2019
5
Formaldehyde as an alternative to antibiotics for treatment of refractory impetigo and other infectious skin diseases. 38
31393185 2019
6
The diagnosis of scabies by non-expert examiners: A study of diagnostic accuracy. 38
31425513 2019
7
Doctors should treat impetigo with antiseptics not antibiotics, says NICE. 38
31416810 2019
8
Human Keratinocytes Use Sphingosine 1-Phosphate and its Receptors to Communicate Staphylococcus aureus Invasion and Activate Host Defense. 38
30807768 2019
9
Topical Ozenoxacin Cream 1% for Impetigo: A Review 38
31334625 2019
10
Wolf's Isotopic Response after Herpes Zoster Infection: A Study of 24 New Cases and Literature Review. 38
31321443 2019
11
Impetigo herpetiformis responsive to secukinumab. 38
31361940 2019
12
Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data. 38
30346521 2019
13
Erratum. 38
31284733 2019
14
Staphylococcus aureus versus neutrophil: Scrutiny of ancient combat. 38
31002964 2019
15
A cluster of acute rheumatic fever cases among Aboriginal Australians in a remote community with high baseline incidence. 38
30994967 2019
16
Echtyma gangrenosum caused by coinfection with group A Streptococcus and Staphylococcus aureus: an emerging etiology? Case reports and literature review. 38
31210583 2019
17
Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. 38
30956111 2019
18
Data augmentation in dermatology image recognition using machine learning. 38
31140653 2019
19
Prevalence of scabies and impetigo three years after mass drug administration with ivermectin and azithromycin. 38
31131410 2019
20
Control of scabies and secondary impetigo: optimising treatment effectiveness in endemic settings. 38
30956112 2019
21
Staphylococcus aureus Antibiotic Susceptibilities in Infections in an Outpatient Dermatology Office on O'ahu. 38
31049265 2019
22
Structures of a highly variable cell-wall anchored protein-encoding the spj gene from ST8/SCCmecIVl community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA/J) isolated from 2003 onwards: An indicator of a strongly invasive pathotype. 38
31009089 2019
23
Localised bullous pemphigoid overlying knee arthroplasty: a diagnostic challenge. 38
30954955 2019
24
Treatment resistant impetigo herpetiformis treated with infliximab. 38
30693621 2019
25
Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. 38
29985978 2019
26
The effect of antimicrobial photodynamic therapy on the expression of biofilm associated genes in Staphylococcus aureus strains isolated from wound infections in burn patients. 38
30684672 2019
27
An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up. 38
30028004 2019
28
Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review. 38
30582783 2019
29
Common Community-acquired Bacterial Skin and Soft-tissue Infections in Children: an Intersociety Consensus on Impetigo, Abscess, and Cellulitis Treatment. 38
30777258 2019
30
Infectious skin disorders encountered in a pediatric emergency department of a tertiary care hospital in Argentina: a descriptive study. 38
30246865 2019
31
Ozenoxacin: a review of preclinical and clinical efficacy. 38
30686133 2019
32
Comparative analysis of methicillin-resistant Staphylococcus aureus isolated from outpatients of dermatology unit in hospitals and clinics. 38
30279113 2019
33
Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. 38
30814052 2019
34
Unraveling the Molecular Mechanism of Selective Antimicrobial Activity of 2(5H)-Furanone Derivative against Staphylococcus aureus. 38
30736278 2019
35
Reliability and accuracy of smartphones for paediatric infectious disease consultations for children with rash in the paediatric emergency department. 38
30704422 2019
36
Staphylococcus aureus and Host Immunity in Recurrent Furunculosis. 38
30995649 2019
37
Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis. 38
29896852 2019
38
Neonatal Birthmarks: A Prospective Survey in 1000 Neonates. 38
30956996 2019
39
Emergence of staphylococcal scalded skin syndrome associated with a new toxinogenic, methicillin-susceptible Staphylococcus aureus clone. 38
30418106 2019
40
Exploration of a simplified clinical examination for scabies to support public health decision-making. 38
30589906 2018
41
Ozenoxacin: A Novel Topical Quinolone for Impetigo. 38
29962213 2018
42
Diffuse facial rash in a former collegiate wrestler. 38
30566114 2018
43
Group A Streptococcus disease in Hong Kong children: an overview. 38
30416105 2018
44
Secondary syphilis presented with impetigo-like lesions: a rare case report. 38
30094832 2018
45
Skin and Soft Tissue Infections in the Emergency Department. 38
30297001 2018
46
Building capacity in primary care: the implementation of a novel 'Pharmacy First' scheme for the management of UTI, impetigo and COPD exacerbation. 38
29362007 2018
47
Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials. 38
30365584 2018
48
Generalized pustular psoriasis: a review and update on treatment. 38
29573491 2018
49
[Pemphigus vulgaris in pediatrics: A case report]. 38
30571809 2018
50
Atypical case of mucous membrane pemphigoid in a 26-year-old man. 38
30209145 2018

Variations for Impetigo

Expression for Impetigo

Search GEO for disease gene expression data for Impetigo.

Pathways for Impetigo

Pathways related to Impetigo according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.17 IL6 CALCA
2 11.05 EDNRB EDNRA
3 10.94 IL6 ELANE
4 10.81 IL6 CALCA
5 10.43 EDNRB EDNRA
6 10.33 EDNRB EDNRA CALCA

GO Terms for Impetigo

Biological processes related to Impetigo according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.65 IL6 IL36RN EDNRB
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.58 EDNRB EDNRA CALCA
3 positive regulation of interleukin-6 production GO:0032755 9.55 IL6 IL36RN
4 positive regulation of smooth muscle cell proliferation GO:0048661 9.54 IL6 ELANE
5 antimicrobial humoral response GO:0019730 9.52 PI3 ELANE
6 monocyte chemotaxis GO:0002548 9.51 IL6 CALCA
7 activation of adenylate cyclase activity GO:0007190 9.49 EDNRA CALCA
8 vasoconstriction GO:0042310 9.37 EDNRB EDNRA
9 regulation of blood pressure GO:0008217 9.33 EDNRB EDNRA CALCA
10 negative regulation of bone resorption GO:0045779 9.32 IL6 CALCA
11 enteric nervous system development GO:0048484 9.26 EDNRB EDNRA
12 vasodilation GO:0042311 9.16 EDNRB
13 response to pain GO:0048265 9.13 EDNRB
14 negative regulation of chemokine biosynthetic process GO:0045079 8.96 IL6 ELANE
15 endothelin receptor signaling pathway GO:0086100 8.62 EDNRB EDNRA

Molecular functions related to Impetigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endothelin receptor activity GO:0004962 8.62 EDNRB EDNRA

Sources for Impetigo

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....